Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;130(1):20-7.
doi: 10.1038/jid.2009.334.

KIT as a therapeutic target in melanoma

Maria C Garrido  1 , Boris C Bastian
Affiliations

KIT as a therapeutic target in melanoma

Maria C Garrido et al. J Invest Dermatol. 2010 Jan.

Abstract

Recently, genetic alterations activating the receptor tyrosine kinase KIT have been shown in some types of melanoma. KIT mutations can be successfully targeted by approved drugs in other cancers. Emerging evidence suggests that melanomas with KIT activation may also respond to KIT inhibitors that are already in clinical use. If confirmed in ongoing clinical trials, this experience would underscore the importance of recognizing the biological diversity among melanomas, representing a first decisive step toward the individualized and mechanism-based treatment of melanoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
See this image and copyright information in PMC

References

    1. Ahrendt SA, Decker PA, Alawi EA, Zhu YrYR, Sanchez-Cespedes M, Yang SC, et al. Cigarette smoking is strongly associated with mutation of the k-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001;92:1525–1530. - PubMed
    1. Alexeev V, Yoon K. Distinctive role of the KIT receptor tyrosine kinase signalling in mammalian melanocytes. J Invest Dermatol. 2006;126:1102–1110. - PubMed
    1. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer. 2007;121:257–264. - PubMed
    1. Ashida A, Takata M, Murata H, Kido K, Saida T. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer. 2009;124:862–868. - PubMed
    1. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hibridization. Cancer Res. 1998;58:2170–2175. - PubMed

MeSH terms

Substances